Vertex Pharmaceuticals has caught investors’ eyes, but its stock performance isn’t exactly a mic-drop moment. Despite massive ...

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The former NFL Comeback Player of the Year shares more about his incredible recovery—and what he wants you to know about pain ...

Vertex Pharmaceuticals's VRTX short percent of float has risen 27.71% since its last report. The company recently reported ...

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics CRSP is currently the only company in the world to have secured approval for a CRISPR-based gene therapy ...

Short interest in Vertex Pharmaceuticals jumped 27.5% in May, hitting 4.82 million shares—just under 2% of the float. This ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

NanoViricides (NNVC) is presenting at the prestigious BIO International Convention on June 16th, showcasing their revolutionary broad-spectrum antiviral platform that could transform how we treat ...